Characterization_NN
of_IN
a_DT
novel_JJ
T_NN
lymphocyte_NN
protein_NN
which_WDT
binds_VBZ
to_TO
a_DT
site_NN
related_JJ
to_TO
steroid\/thyroid_JJ
hormone_NN
receptor_NN
response_NN
elements_NNS
in_IN
the_DT
negative_JJ
regulatory_JJ
sequence_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
long_JJ
terminal_JJ
repeat_NN
._.

We_PRP
have_VBP
previously_RB
identified_VBN
a_DT
T_NN
lymphocyte_NN
protein_NN
which_WDT
binds_VBZ
to_TO
a_DT
site_NN
within_IN
the_DT
LTR_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HIV-1_NN
-RRB-_-RRB-
and_CC
exerts_VBZ
an_DT
inhibitory_JJ
effect_NN
on_IN
virus_NN
gene_NN
expression_NN
._.

The_DT
palindromic_JJ
site_NN
-LRB-_-LRB-
site_NN
B_NN
-RRB-_-RRB-
recognized_VBN
by_IN
this_DT
protein_NN
is_VBZ
related_JJ
to_TO
the_DT
palindromic_JJ
binding_VBG
sites_NNS
of_IN
members_NNS
of_IN
the_DT
steroid\/thyroid_JJ
hormone_NN
receptor_NN
family_NN
._.

Here_RB
we_PRP
characterize_VBP
the_DT
T_NN
cell_NN
protein_NN
binding_NN
to_TO
this_DT
site_NN
as_IN
a_DT
100_CD
kD_NN
protein_NN
which_WDT
is_VBZ
most_RBS
abundant_JJ
in_IN
T_NN
cells_NNS
and_CC
which_WDT
binds_VBZ
to_TO
site_NN
B_NN
as_IN
a_DT
200_CD
kD_NN
complex_NN
._.

This_DT
protein_NN
is_VBZ
distinct_JJ
from_IN
other_JJ
members_NNS
of_IN
the_DT
steroid\/thyroid_JJ
hormone_NN
receptor_NN
family_NN
including_VBG
the_DT
COUP_NN
protein_NN
which_WDT
has_VBZ
a_DT
closely_RB
related_JJ
DNA_NN
binding_NN
specificity_NN
._.

